Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

Amicus Therapeutics announced that the European Commission has granted approval for Pombiliti™, a long-term enzyme replacement therapy used in combination with miglustat for adults with late-onset Pompe disease.